2023
CAR TCR Europe
Transitioning from a multi modular system to a single automated device for TCR T production; Dolores Schendel
2022
Cell UK
High Fidelity Production of TCR-T Cells from Elderly Hematologically-Challenged Patients With Blood Cancers; Dolores Schendel
CHI Immuno-Oncology Summit
TCR-Ts overcoming TME hurdles by switching immunosuppression to T cell activation with integrated Switch Receptor Technology; Dolores Schendel
Immuno UK
Immune monitoring tools and their application; Petra Prinz
CAR-TCR Summit
Combined Molecular & Cellular Tools are Required to Assess Safety of TCR-T Immunotherapies; Tristan Holland
Next Generation CAR-TCR Summit
Identify Peptide Targets for TCR-Ts Derived from Non-Coding RNA Sequences; Justyna Ogonek
2021
ESMO Immuno-Oncology Congress
The inducible Medigene T cell receptor ( iM TCR) controls cytotoxicity of tumor specific TCR modified T cells with improved avidity through control of TCR surface expression, Andreas Acs, Adriana Turqueti Neves, Justyna Ogonek, Barbara Loesch, Dolores J. Schendel, Slavoljub Milosevic
Cellular Immunotherapies for Solid Tumors Summit
Empowering TCR-Ts to infiltrate, proliferate and control solid tumors in a hostile tumor microenvironment, Dolores Schendel
SITC 2021
Targeting a novel shared tumor-specific antigen with T cell receptor transduced T cells for the treatment of ovarian cancer Justyna Ogonek, Tiziana Franceschetti, Andreas Acs, Alexander Schmidt, Alexandra Kuhlenkamp, Krystel Vincent, Claude Perreault, Barbara Loesch, Adriana Turqueti Neves, Slavoljub Milosevic, Dolores J. Schendel and Daniel Sommermeyer
Neoantigen Based Therapies Summit
Dark Matter Antigens: Exploration with Molecular and Cellular Tools; Dolores Schendel
ESMO
T cells transgenic for a highly potent PRAME-specific TCR and a chimeric PD1-41BB co-stimulatory receptor represent a promising approach for the treatment of solid tumors; Maja Bürdek, Ina Fetzer, Nadja Sailer, Melanie Salvermoser, Doris Brechtefeld, Kathrin Mutze, Silke Raffegerst, Monika Braun, René Goedkoop, Susanne Wilde, Daniel Sommermeyer
TCR-based Therapies Summit
T cells equipped with both a highly potent PRAME-specific T cell receptor and a chimeric PD1-41BB co-stimulatory receptor show superior in vitro and in vivo tumor reactivity; Nadja Sailer, Ina Fetzer, Melanie Salvermoser, Doris Brechtefeld, Maja Bürdek, Kathrin Mutze, Monika Braun, Dolores J. Schendel, Susanne Wilde, Daniel Sommermeyer
Helping TCR-Ts Meet the Challenges of the TME; Dolores J. Schendel
Presentation
CIMT 2021
Inducible Medigene T cell receptor (iM-TCR): Controlled cytotoxicity of tumor-specific TCR-modified T cells with improved avidity through control of TCR surface expression; Adriana Turqueti Neves, Andreas Acs, Justyna Ogonek, Barbara Loesch, Dolores J. Schendel, Slavoljub Milosevic
T cells expressing a highly potent PRAME-specific T cell receptor equipped with a PD1-41BB switch receptor show a favorable preclinical safety profile, strong anti-tumor reactivity and superior fitness; Nadja Sailer, Ina Fetzer, Melanie Salvermoser, Doris Brechtefeld, Maja Bürdek, Kathrin Mutze, Monika Braun, Susanne Wilde, Daniel Sommermeyer
Tumor specific antigens derived from non-mutated non-coding regions of the genome can be targeted by T-cell receptor-transgenic T cells; Anna Schleicher, Alexandra Kuhlenkamp, Qingchuan Zhao, Krystel Vincent, Claude Perreault, Slavoljub Milosevic, Tiziana Franceschetti, and Daniel Sommermeyer
AACR 2021
Combining a PRAME-specific TCR showing potent in vitro and in vivo anti-tumor reactivity and a favorable preclinical safety profile with a PD1-41BB switch receptor results in highly efficient T cells; Ina Fetzer, Nadja Sailer, Melanie Salvermoser, Manon Weis, Christian Krendl, Maja Bürdek, Doris Brechtefeld, Isabella Rampp, Julian Rydzek-Wiesner, Monika Braun, Christian Ellinger, Christiane Geiger, Daniel Sommermeyer, Susanne Wilde
Poster [nomenclature adapted]
Targetable immunogenic tumor specific antigens can be identified in non-coding regions of the genome; Franceschetti T, Zhao Q, Vincent K, Perreault C, Milosevic S and Sommermeyer D
TCT 2021
Long term follow up of a ‘fast-DC’ immunotherapy against WT-1 and PRAME as a post-remission strategy for AML; Yngvar Fløsand, MD PhD, Mats Remberger, MD PhD, Iris Bigalke, MD, Dag Josefsen, MD PhD, Richard Addo, MD PhD, Dolores Schendel, PhD, Kai Pinkernell, MD, Gunnar Kvalheim, MD PhD
2020
ASH Annual Meeting and Exposition 2020
A WT-1 and PRAME “Fast-DC” Immunotherapy As a Potential Post-Remission Strategy for AML; Yngvar Floisand, MD, PhD, Iris Bigalke, MD, Dag Josefsen, MD, PhD, Silke Raffegerst, PhD, Frauke Schnorfeil, PhD, Richard Addo, MD, PhD, Dolores J. Schendel, PhD, Kai Pinkernell, MD, Gunnar Kvalheim, MD, PhD
PRAME mRNA Expression in AML/MDS and HLA Genotype Analysis: Impact on Population Coverage and Design of TCR-Based Immunotherapies; Richard Addo, MD, PhD, Kathrin Davari, PhD, Silke Raffegerst, PhD, Dolores Schendel, PhD, Kai Pinkernell, MD, Simone Thomas, MD
SITC Annual Meeting 2020
Co-stimulation via PD1 41BB chimeric switch receptor enhances function of TCR T cells in an immune suppressive milieu and under chronic antigen stimulation; Melanie Salvermoser, Maria Gerget , Franziska Hasselmann, Elfriede Noessner, Christian Ellinger, Monika Braun, Dolores J. Schendel, Daniel Sommermeyer and Nadja Sailer
SITC Annual Meeting 2020
Consistent high-quality dendritic cell vaccines produced post-chemotherapy in patients with acute myeloid leukemia for use in a Phase I/II trial; Frauke Schnorfeil, Christiane Geiger, Iris Bigalke, Dag Josefsen, Yngvar Floisand, Gunnar Kvalheim, Dolores J. Schendel, Anna Tafuri, Kai Pinkernell
SITC Annual Meeting 2020
Development of a CD8 co-receptor independent T cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T cell-based immunotherapy; Davari K, Holland T, Prassmayer L, Longinotti G, Ganley K, Pechilis LJ, Diaconu I, Nambiar PR, Magee MS, Schendel DJ, Sommermeyer D and Ellinger C
AACR Virtual Annual Meeting II
The chimeric co-stimulatory receptor PD1-41BB enhances the function of T cell receptor (TCR)-modified T cells targeting solid tumors; Nadja Sailer, Melanie Salvermoser, Maria Gerget, Sarah Thome, Angelika J. Fischbeck, Svenja Ruehland, Luis F. Olguín-Contreras, Maja Buerdek, Christian Ellinger, Elfriede Noessner, Dolores J. Schendel, Patrik Kehler.
Medigene Immunotherapies GmbH, Planegg/Martinsried, Germany, Helmholtz Zentrum München, Munich, Germany, Medigene AG, Planegg/Martinsried, Germany
2019
ASH – American Society of Hematology Annual Meeting 2019, Orlando
DC Vaccination Induces Antigen Specific Immune Responses in AML Patients: A 1-Year Interim Assessment; Judith Eckl, PhD, Silke Raffegerst, PhD, Frauke Schnorfeil, PhD, Petra Prinz-Schulz, PhD, Christiane Fingerhut, Yngvar Floisand, MD, PhD, Dag Josefsen, Iris Bigalke, MD, Kai Pinkernell, MD, MBA, Gunnar Kvalheim, MD, PhD, Dolores Schendel, Prof. and Anna Tafuri, MD
SITC – Society for Immunotherapy of Cancer Annual Meeting 2019, National Harbor MD, USA
A. Bracher, S. Milosevic and D. Sommermeyer 2019. Targeting neoantigens with immunotherapy: Are we limited to pre-existing autologous neoantigen-specific T cells? SITC National Harbor, USA.
Congress of the European Hematology Association – EHA 2019, Amsterdam
CIMT – Annual Meeting of the Association for Cancer Immunotherapy 2019, Mainz, Germany
A safe and highly active NY-ESO-1/LAGE-1-specific TCR for adoptive T cell therapy of cancer; Longinotti G, Bürdek M, Weis M, Raffegerst S, Mösch A, Schendel DJ, Wehner C
2018
ASH – American Society of Hematology Annual Meeting 2018, San Diego
Immune Monitoring of Vaccine Quality and Persistence of Specific T Cell Responses in Five AML Patients Receiving Extended Dendritic Cell Vaccination Under Compassionate Use; Iris Bigalke, Judith Eckl, PhD, Guri Solum, MSc, Kirsti Hønnåshagen, Msc, Lisbeth Skoge, MSc, Yngvar Fløisand, MD, PhD, Dag Josefsen, MD, PhD, Stein Sæbøe-Larssen, PhD, Christiane Geiger, PhD, Dolores Schendel, PhD and Gunnar Kvalheim, MD, PhD.
AACR – American Association for Cancer Research Annual Meeting 2018, Chicago, USA
2017
AACR – American Association for Cancer Research Annual Meeting 2017, Washington, D.C., USA
WT1 and PRAME mRNA transfected TLR 7/8-polarized fast DC vaccines in AML patients mount specific immune responses and impact progression free survival; Iris Bigalke, Guri Solum, Dag Josefsen, Yngvar Fløisand, Kirsti Hønnåshagen, Lisbeth Skoge, Signe Spetalen, Stein Sæbøe-Larssen, Dolores J. Schendel, Gunnar Kvalheim.
Isolation and characterization of a PRAME-specific TCR with high avidity, potent antitumor efficacy and a favorable preclinical safety profile; Manon Weis, Carina Wehner, Christian Ellinger, Susanne Wilde, Dolores J. Schendel. Medigene Immunotherapies GmbH, Planegg/Martinsried, Germany
2016
Neoantigen Summit 2016, Boston, USA
Targeting neoantigens by TCR therapy: Are we limited to treatment of tumors with highmutational loads and patients with pre-existing neoantigen-specific T cells? Dolores J. Schendel, CEO and CSO Medigene AG, Munich Germany
ACCR – American Association for Cancer Research 2016, New Orleans, LA, USA
Tryggestad A., Axcrona K., Bigalke I., Inderberg-Suso, E., Skorstad, G., Axcrona U., Aamdal S., Gaudernack G., Schendel D., Lilleby W., Dueland S. and Kvalheim G. 2016. Clinical results of a Phase I/II trial of adjuvant therapeutic vaccination in high risk resected prostate cancer patients using autologous dendritic cells loaded with mRNA from primary prostate cancer tissue, hTERT and survivin. AACR, New Orleans, USA
2015
ASH – American Society of Hematology Annual Meeting 2015, Orlando FL, USA
Bigalke I., Fløisand Y., Solum G., Hønnåshagen K., Lundby M., Anderson K., Sæbøe-Larssen S., Inderberg E., Eckl J., Schendel D., and Kvalheim G. 2015. AML Patients in Minimal Residual Disease Vaccinated with a Novel Generation of Fast Dendritic Cells Expressing WT-1 and PRAME Mount Specific Immune Responses That Relate to Clinical Outcome. ASH Orlando, USA.
Phacilitate Immunotherapy Forum 2015, Washington DC, USA
Schendel D. 2014. Tailoring immunotherapies for patients with different stages of prostate cancer. Phacilitate Conference Washington DC, USA.
2014
ASH – American Society of Hematology Annual Meeting 2014, San Francisco, USA
Bigalke I., Honnashagen K., Lundby M., Kasten J., Suso Inderberg E., Skoge L., Saboe-Larssen S., Schendel D., Kvalheim G. 2014. 2440 Vaccination with a New Generation of Fast Dendritic Cells Transfected with mRNA from hTERT, Survivin and Autologous Tumor Mount Strong Immune Responses and Prolong Survival. ASH San Francisco, USA.
SITC – Society for Immunotherapy of Cancer Annual Meeting 2014, National Harbor MD, USA
Schnorfeil F., Lichtenegger F., Geiger C., Köhnke T., Bücklein V., Altmann T., Wagner B., Henschler R., Bigalke I, Kvalheim G., Hiddemann W., Schendel D.J., Subklewe M. 2014. Next-generation dendritic cells for immunotherapy of acute myeloid leukemia. SITC National Harbor, USA.
SITC – Society for Immunotherapy of Cancer Annual Meeting 2014, National Harbor MD, USA
Wehner C., Ellinger C., Raffegerst S., Wilde S., Mosetter B., Weis M., Longinotti G., Sailer N., Schendel D.J., Milošević S. 2014. Generation of tumor antigen specific CD4+ and CD8+ T cells by simultaneous MHC-I and –II epitope presentation in vitro and in vivo. SITC National Harbor, USA.
PIVAC – Progress in Vaccination Against Cancer 2014, Rom
Tryggestad A., Axcrona K., Bigalke I.,MInderberg-Suso E., Skorstad G, Axcrona U.,Steinar A., Gaudernack G.,Lilleby W., Dueland S., Kvalheim G. 2014. A PhaseI/II trial of adjuvant therapeutic vaccination in resected prostate cancer patients using autologous dendritic cells loaded with mRNA from primary prostate cancer tissue,hTERT and survivin. PIVAC Rome, Italy.
Rampp I., Eichenlaub S., Römer I., Pohla H., Bigalke I., Sæbøe-Larssen S., Krackhardt A., Schendel D.J. Geiger C. 2014. Evaluation of a new generation dendritic cell-based vaccine for treatment of patients with castration-resistant prostate cancer. PIVAC Rome, Italy.
1st Immunotherapy of Cancer Conference 2014, München
Lichtenegger F., Beck B., Geiger C., Bigalke I., Kvalheim G., Hiddemann W., Schendel D., Subklewe M. 2014. Dendritic cell vaccination for postremission therapy in AML. ITOC Munich, Germany.
CIMT – Cancer Immunotherapy Annual Meeting 2014, Mainz
Tryggestad A.M.A., Bigalke I., Skorstad G., Skoge L.J., Honnashagen T.K., Axcrona K., Lilleby W., Kvalheim G. 2014. Cancer vaccines with hTERT and Survivin mRNA transfected fast DCs – a simplified and effective cancer vaccine. CIMT Mainz, Germany.
Schnorfeil F.M., Lichtenegger F.S., Geiger C., Beck B., Koehnke T., Buecklein V., Altmann T., Wagner B., Henschler R., Bigalke I., Kvalheim G., Hiddemann W., Schendel D.J., Subklewe M. 2014. Next-generation dentritic cell vaccination as postremission therapy in AML. CIMT Mainz, Germany.
Rampp I.S., Eichenlaub S., Römer I., Pohla H., Bilgalke I., Saeboe-Larssen S., Schendel D.J., Geiger C. 2014. Development of a next generation dentritic cell-based immunotherapie for patients with castration-resistant prostate cancer. CIMT Mainz, Germany.
Lorenz F.K.M., Wilde S., Voigt K., Kieback E., Schendel D.J., Uckert W. 2014. Gene optimization can generate cryptic epitopes that induce T cell responses. CIMT Mainz, Germany.
Bigalke I.,Honnashagen K., Lundby M., Kasten J., Inderberg Suso E.-M., Skoge L., Saboe-Larssen S., Schendel D.J., Kvalheim G. 2014. First clinical experience with a new generation of fast DCs transfected with mRNA from hTERT, survivin and autologous tumor. CIMT Mainz, Germany.
BioM seminar series 2014: m4-personalized medicine, München
Dr. Geiger C. 2014. A dendritic cell-based immunotherapy for patients with castration-resistant prostate cancer (CRPC). BioM Munich, Germany.
BioM forum 2014: Development and approval of ATMPs, München
Dr. Geiger C. 2014. “Dendritische Zellvakzine zur Behandlung minimaler residualer Krebserkrankungen – Discovery und Präklinik” (A dendritic cell vaccine for treatment of patients with minimal residual disease – discovery and pre-clinical development). BioM Munich, Germany.
Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V. Jahrestagung 2014, Hamburg
Kobold S., Steffen J., Chaloupka M., Grassmann S., Henkel J., Castoldi R., Yi Zeng, Chmiliewski M., Schmollinger J., Schnurr M., Rothenfußer S., Schendel D.J., Abken H., Sustmann C, Niederfellner G., Klein C., Bourquin C., Endres S. 2014. Bispecific T cell recruiting antibody enhances anti-tumor activity of adoptive T cell transfer. DGHO Hamburg, Germany.
European Society for Blood and Marrow Transplantation Annual Meeting 2014, Mailand
von Luettichau I., Salat C., Wawer A., Noessner E., Eckl J., Multhoff G., Thiel U., Issels R.D., Kolb H.J., Burdach S. 2014. Targeting the Graft-Versus-Tumor Effect of DLI by Regional Hyperthermia to the Tumor Compartment. EBMT Milan, Italy.
2013
CIMT – Cancer Immunotherapy Annual Meeting 2013, Mainz
Ellinger C., Wehner C., Wilde S., Schendel D.J., Milošević S. Mai 2013. MHC Class-II Expression Targeting (CrossTAg) for the Generation of Tumor-Antigen-Specific CD4+ T Lymphocytes. CIMT Mainz, Germany.
CIMT – Cancer Immunotherapy Annual Meeting 2013, Mainz
Wehner C., Ellinger C., Raffegerst S., Wilde S., Mosetter B., Schendel D.J., Milošević S., 2013. Isolation of antigen-specific CD8+ T lymphocytes and molecular characterization of antigenic epitopes. CIMT Mainz, Germany.
SITC – Society for Immunotherapy of Cancer Annual Meeting 2013, National Harbor MD (USA)
Ellinger C., Wehner C., Wilde S., Schendel D.J., Milošević S. 2013. Induction and isolation of tumor antigen-specific CD4+ T lymphocytes using sorting signal directed MHC class-II expression. SITC National Harbor MD, USA.
Wehner C., Ellinger C., Raffegerst S., Wilde S., Mosetter B., Schendel D.J., Milošević S. 2013. Isolation of antigen-specific CD8+ T lymphocytes in vitro and in vivo. SITC National Harbor MD, USA.
Geiger C., Beck B., Bigalke I., Lichtenegger F.S., Heemskerk M., Saboe-Larssen S., Kvalheim G., Schendel D.J., Subklewe M. 2013. A new generation of dendritic cells optimized for the use in active immunotherapy – preclinical evaluation without an animal model. SITC National Harbor MD, USA.
Helmholtz Alliance 2013, Asselheim
Marin V., Longinotti G. 2013. Status of GMP process development for TCR expression in lymphocytes. Helmholtz Alliance Asselheim, Germany.
Marin V., Longinotti G., Wieczorek A., Willde S., Mosetter B., Raffegerst S., Eckl J., Ellinger C., Frankenberger B., Leisegang M., Uckert W., Spranger S., Uharek L., Schendel D. 2013. Setting up of a GMP-compliant method for the production of human TCR-transduced T cells for the clinical testing. Helmholtz Alliance Asselheim, Germany.
Cellular Therapie International Symposium 2013, Erlangen
Wilde S., Mosetter B., Wehner C., Ellinger C., Milosevic S., Frankenberger B., Schendel D. 2013. Isolation of NY-ESO-1-specific T cell receptors restricted by non-HLA-A*02:01 allotypes for TCR gene therapy. Cellular Therapie International Symposium Erlangen, Germany.
Cellular Therapie International Symposium 2013, Erlangen
Geiger C., Beck B., Bigalke I., Lichtenegger F.S., Heemskerk M., Saboe-Larssen S., Kvalheim G., Schendel D.J., Subklewe M. 2013. A DC-based therapeutic vaccine for AML patients: preclinical evaluation of a new generation of DCs expressing the leukemia-associated antigens WT1 and PRAME. Cellular Therapie International Symposium Erlangen, Germany.
Tumor specific antigens derived from non-mutated non-coding regions of the genome can be targeted by T-cell receptor-transgenic T cells; Anna Schleicher, Alexandra Kuhlenkamp, Qingchuan Zhao, Krystel Vincent, Claude Perreault, Slavoljub Milosevic, Tiziana Franceschetti, and Daniel Sommermeyer
ASH – American Society of Hematology Annual Meeting 2013, New Orleans LA (USA)
Lichtenegger F.S., Beck B., Geiger C., Munker D., Schlueter M., Draenert R., Kvalheim G., Hiddemann W., Schendel D.J., Subklewe M. 2013. Improving Efficacy of Dendritic Cell Vaccination in AML: Optimization of the DC Generation Protocol and Maximization of T Cell Responses by Immune Checkpoint Blockade. ASH New Orleans LA, USA.
Keystone Symposia 2013, USA
Smith S., Sommermeyer D., Schmitt T., Schendel D.J., Bernhard H., Piepenbrink K., Baker B., Blankenstein T., Uckert W., Greenberg P., Kranz D. 2013. Engineering high-affinity human single-chain T cell receptors against cancer antigens. Keystone Symposia, USA.
Acute Leukemias XIV, International Symposium 2013, München
PD Dr. Subklewe M. 2013. Dendritic Cell Vaccination for Postremission Therapy in AML. Acute Leukemias XIV München, Germany.
European Society for Blood and Marrow Transplantation Annual Meeting 2013, London (UK)
Wieczorek A., Marin V., Raffegerst S., Wilde S., Mosetter B ., Spranger S., Frankenberger B., Leisegang M., Uckert W., Uharek L., Schendel D.J. 2013. HMMR-redirected adoptive T cell therapy for treatment of refractory acute myeloid leukemia in context of mismatched stem cell transplantation. EBMT London, UK.
2012
SFB TR 36 Annual Meeting 2012 Berlin
Wilde S., Sommermeyer D., Leisegang M., Frankenberger B., Mosetter B., Uckert W., Schendel D.J. 2012. Human antitumor CD8+ T cells producing Th1-polycytokines show superior antigen sensitivity and tumor recognition. SFB TR 36 Berlin, Germany.